Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Filip Janku Sells 11,845 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 11,845 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $20.22, for a total transaction of $239,505.90. Following the sale, the insider owned 59,992 shares in the company, valued at approximately $1,213,038.24. The trade was a 16.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Filip Janku also recently made the following trade(s):

• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total transaction of $642,600.00.

Monte Rosa Therapeutics Trading Up 3.9%

Shares of NASDAQ GLUE opened at $21.66 on Friday. The firm has a market cap of $1.83 billion, a PE ratio of -14.64 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77. The company has a fifty day moving average price of $18.88 and a 200 day moving average price of $18.61.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Equities research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. JPMorgan Chase & Co. boosted their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Guggenheim decreased their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Wells Fargo & Company lowered their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its position in Monte Rosa Therapeutics by 10.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after purchasing an additional 481,844 shares during the last quarter. Vanguard Group Inc. grew its stake in Monte Rosa Therapeutics by 8.6% in the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after purchasing an additional 257,547 shares in the last quarter. State Street Corp increased its position in shares of Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Monte Rosa Therapeutics by 459.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Monte Rosa Therapeutics by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after purchasing an additional 53,278 shares in the last quarter. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.